Cervical Colposcopy: Indications and Risk Assessment.

Area of Science:

• Gynecology
• Oncology
• Preventive Medicine

Background:

• Colposcopy practice has evolved to integrate patient risk factors for high-grade cervical intraepithelial neoplasia (CIN) and cancer.
• Recent updates in cervical cancer screening, HPV vaccination, and ASCCP colposcopy standards impact primary care.
• Primary care clinicians play a crucial role in managing cervical cancer risk and screening.

Purpose of the Study:

• To inform primary care clinicians about updated colposcopy practices and cervical cancer screening guidelines.
• To emphasize the importance of HPV vaccination and risk factor assessment in cervical cancer prevention.
• To guide clinicians in managing abnormal cytology, HPV testing, and CIN based on current ASCCP recommendations.

Main Methods:

• Review of current cervical cancer screening guidelines, including HPV vaccination recommendations.
• Analysis of risk factors (cytology, HPV subtype, persistence) for high-grade CIN and cancer.
• Guidance on shared decision-making for colposcopy, biopsies, and LEEP procedures.
• Emphasis on clinic-based systems for follow-up of abnormal screening results and diagnosed CIN.

Main Results:

• Primary care clinicians should offer HPV vaccination to patients aged 9-26.
• Risk stratification using cytology, HPV type, and infection persistence is essential for management.
• Specific criteria guide decisions for colposcopy, biopsies, or immediate LEEP for high-risk patients.
• Long-term surveillance is recommended for patients with CIN 2 or worse.

Conclusions:

• Primary care clinicians must be knowledgeable about the 2019 ASCCP guidelines for cervical cancer screening and follow-up.
• Integrating HPV vaccination, risk factor assessment, and appropriate colposcopy management is key to preventing cervical cancer.
• Developing robust clinic systems ensures timely and accurate follow-up for patients with abnormal screening results or diagnosed CIN.